For Healthcare Professionals

To Evaluate SCTA01 Treatment of High-risk Outpatients With COVID-19


About the study

The study is a multicenter, adaptive, randomized, double-blinded and placebo-controlled Phase II/III clinical trial. It will be conducted at selected investigational sites globally. The study is comprised of 2 parts.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Inclusion Criteria:

  1. Male or non-pregnant female adults, ≥18 years old of age at the time of randomization;
  2. Participants should have at least one of COVID-19 risk factor;
  3. Participants should have at least 2 COVID-19 related symptoms;
  4. Has symptoms consistent with COVID-19 as determined by the investigator with onset ≤7 days before randomization;
  5. First positive SARS-CoV-2 viral infection tested (PCR or antigen-based diagnostic tests) in samples collected ≤3 days prior to start of the infusion;
  6. Participants are currently not hospitalized;
  7. Participant (or legal authorized representative) has signed the ICF before any clinical activity related to SCTA01 trial;
  8. Women with childbearing potential must agree to use effective contraceptive methods during the study period;
  9. Patient should not participate in other clinical studies related to COVID-19 or SARS-CoV-2 infection.


Exclusion Criteria:

  1. Have known allergies to any of the components used in the formulation of the SCTA01/placebo;
  2. Participants with a history of severe anaphylaxis, such as severe anaphylactic reaction, urticaria, and angioedema;
  3. Have SpO2 ≤ 93% on room air at sea level or PaO2/FiO2 < 300, respiratory rate ≥30 per minute, heart rate ≥125 per minute (FDA);
  4. Require mechanical ventilation or anticipated impending need for mechanical ventilation;
  5. Suspected or proven serious bacterial, fungal, viral, or other infection (besides COVID-19) that in the opinion of the investigator could constitute a risk when taking part in this study;
  6. Have any serious concomitant systemic disease, condition or disorder that, in the opinion of the investigator, should preclude participation in this study;
  7. Have any co-morbidity requiring surgery within <29 days, or that is considered life threatening within 29 days;
  8. Have a history of previous SARS-CoV-2 infection;
  9. Received convalescent plasma, COVID-19 vaccine, or anti-SARS-CoV-2 spike(S) protein targeted therapy;
  10. Have participated in a clinical study involving an investigational intervention within past 30 days or 5-half lives of investigational product, whichever is longer;
  11. Have received an investigational intervention for SARS-CoV-2 prophylaxis within 30 days before dosing;
  12. Pregnant or lactating women;
  13. Anticipated hospitalization or transfer to another medical site which is not a study site within 72 hours;
  14. Participants unable to follow the protocol during the study;
  15. Participants deemed inappropriate for enrollment by the investigator due to other factors.
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details



Age (in years)



Phase 2/Phase 3

Participants needed


Est. Completion Date

Mar 1, 2022

Treatment type



Sinocelltech Ltd. identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.